In This Section

adamson [at]
Location - People View
Room 10030

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Research Topics
Peter C. Adamson, MD
Peter C. Adamson
Chair, Children’s Oncology Group

Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.



Subscribe to be notified of changes or updates to this page.


Dr. Adamson is chair of the Children’s Oncology Group (COG), a National Cancer Institute-supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer.

He was appointed by President Obama and serves on the National Cancer Advisory Board (NCAB) and has served as a member of the Blue Ribbon Panel for Vice President Biden’s National Cancer Moonshot Initiative.

Prior to becoming chair of the COG in 2011, Dr. Adamson was director for Clinical and Translational Research at Children’s Hospital as well as chief of the Division of Clinical Pharmacology and Therapeutics. Other past roles include being co-director of the University of Pennsylvania-CHOP Clinical Translational Science Award, program director of the General Clinical Research Center and principal investigator of CHOP’s Pediatric Pharmacology Research Unit.

His laboratory work focuses on the clinical pharmacology of new drugs for childhood cancer.

Education and Training

BA, Wesleyan University (Chemistry), 1980

MD, Cornell University Medical College, 1984

Fellowship, National Cancer Institute (Pediatric Hematology/Oncology), 1990

Titles and Academic Titles

Chair, Children’s Oncology Group

Alan R. Cohen Endowed Chair in Pediatrics

Professor of Pediatrics

Professional Memberships

American Society for Clinical Pharmacology and Therapeutics

American College of Clinical Pharmacology

American Association for Cancer Research

American Society of Clinical Oncology

American Society of Pediatric Hematology/Oncology

Society for Pediatric Research

National Cancer Advisory Board

Biden Cancer Initiative Advisory Committee

Professional Awards

Ritter Award for Overall Excellence in Clinical and Interpersonal Skills, Children's Hospital of Philadelphia, 1987

Children's Cancer Foundation Research Scholar, 1992

Special Recognition Award for Exceptional Service to the Clinical Trials Working Group of the National Cancer Advisory Board, National Cancer Institute, 2005

Director's Service Award for Outstanding and Dedicated Service to the Institute and the Clinical Trials and Translational Research Advisory Committee, National Cancer Institute, 2013

Publication Highlights

Das S, Rousseau R, Adamson PC, Lo AW. New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review. JAMA Oncol. 2018 Sep; 4(9):1274-1280. PMID: 29860493
Adamson PC. Improving the outcome for children with cancer: Development of targeted new agents. CA Cancer J Clin. 2015 May; 65(3):212-20. PMID: 25754421
Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80. PMID: 23598171
Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013 Mar; 14(3):e117-24. PMID: 23434337
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC, Childhood Absence Epilepsy Study G. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar; 362(9):790-9. PMID: 20200383

Links of Interest